Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".

Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators.

Mov Disord. 2011 Aug 15;26(10):1864-8. doi: 10.1002/mds.23741. Epub 2011 Apr 29.

2.

Genome-wide variant by serum urate interaction in Parkinson's disease.

Nazeri A, Roostaei T, Sadaghiani S, Chakravarty MM, Eberly S, Lang AE, Voineskos AN.

Ann Neurol. 2015 Nov;78(5):731-41. doi: 10.1002/ana.24504. Epub 2015 Aug 29.

PMID:
26284320
3.

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J.

Arch Neurol. 2008 Jun;65(6):716-23. doi: 10.1001/archneur.2008.65.6.nct70003. Epub 2008 Apr 14.

4.

Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.

J Nucl Med. 1998 Sep;39(9):1500-8.

5.

Uric acid relates to dopamine transporter availability in Parkinson's disease.

Moccia M, Pappatà S, Erro R, Picillo M, Vitale C, Amboni M, Longo K, Palladino R, Barone P, Pellecchia MT.

Acta Neurol Scand. 2015 Feb;131(2):127-31. doi: 10.1111/ane.12295. Epub 2014 Oct 7.

PMID:
25288358
6.

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA.

J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133-40.

7.
8.

SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.

Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T.

J Neurol Sci. 2001 Jun 15;187(1-2):55-9.

PMID:
11440745
9.

Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.

Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.

J Nucl Med. 1998 Jul;39(7):1143-8.

10.

Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.

Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, van Royen EA.

Eur J Nucl Med. 1997 Jan;24(1):68-71.

PMID:
9044880
11.

Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.

Kim HJ, Im JH, Yang SO, Moon DH, Ryu JS, Bong JK, Nam KP, Cheon JH, Lee MC, Lee HK.

J Nucl Med. 1997 Nov;38(11):1703-11.

12.

Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, Charney DS, van Dyck CH, Hoffer PB, Innis RB.

J Nucl Med. 1997 Sep;38(9):1453-9.

14.

Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.

Di Giuda D, Calcagni ML, Totaro M, Cocciolillo F, Piano C, Soleti F, Fasano A, Cioni B, Bentivoglio AR, Giordano A.

Nucl Med Commun. 2012 Sep;33(9):933-40. doi: 10.1097/MNM.0b013e3283561810.

PMID:
22735298
15.

Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.

Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB.

Ann Neurol. 1998 Jun;43(6):792-800.

PMID:
9629849
16.

Levodopa and the progression of Parkinson's disease.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group.

N Engl J Med. 2004 Dec 9;351(24):2498-508.

17.
18.
19.

Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.

Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J.

Nucl Med Commun. 2001 Jun;22(6):721-5.

PMID:
11403185
20.

One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.

Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA.

J Nucl Med. 1999 May;40(5):753-61.

Supplemental Content

Support Center